Last Updated : July 22, 2024
Details
FilesGeneric Name:
olopatadine hydrochloride and mometasone
Project Status:
Active
Therapeutic Area:
Seasonal allergic rhinitis
Manufacturer:
Bausch Health
Call for patient/clinician input open:
Brand Name:
Ryaltris
Project Line:
Reimbursement Review
Project Number:
SR0848-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 10-May-24 |
|---|---|
| Call for patient/clinician input closed | 08-Jul-24 |
| Submission received | 21-Jun-24 |
| Submission accepted | 08-Jul-24 |
| Review initiated | 09-Jul-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 23-Sep-24 |
| Deadline for sponsors comments | 03-Oct-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 15-Nov-24 |
| Expert committee meeting (initial) | 27-Nov-24 |
| Draft recommendation issued to sponsor | December 09, 2024 To December 11, 2024 |
| Draft recommendation posted for stakeholder feedback | 19-Dec-24 |
| End of feedback period | 10-Jan-25 |
Files
Last Updated : July 22, 2024